The metabolic benefits they produce have implications for cardiovascular disease, liver health, diabetes management, and more
Side Effects and Adverse Events The side effects for both medications are generally gastrointestinal, particularly during the dose-escalation phase: Nausea Vomiting Constipation Diarrhea Rare but serious adverse events include: Pancreatitis Thyroid tumors (observed in animal studies) Hypoglycemia when combined with other glucose-lowering drugs Tolerability varies by individual, and while most side effects diminish over time, they remain a barrier to long-term adherence for some patients
Ledezma-Tejeida D
Where a claim rests on retracted work, that status is stated alongside it
Another amylin and GLP-1 agonist pair being developed by Novo Nordisk is amycretin
Rhodes ET, Goran MI, Lieu TA, Lustig RH, Prosser LA, Songer TJ, Weigensberg MJ, Weinstock RS, Gonzalez T, Rawluk K, Zoghbi RM, Ludwig DS, Laffel LM: Health-related quality of life in adolescents with or at risk of type 2 diabetes